--:--:--
Stockwatch Reports
…

Coverage / Healthcare / CELC

Next Report: FNV
CELCCelcuity Inc.

NasdaqCM · Healthcare · Mkt cap $3.9B · Avg vol 1.15M

$64.37

+0.20 (+0.31%)

Quote as of November 15, 2026, 12:23 PM ET

Initiating coverage · Published September 30, 2026, 9:48 AM ET

A High-Risk/High-Reward Bet on First-in-Class PI3K/mTOR Inhibition in Breast Cancer

Share
$138.23$111.01$83.80$56.58Initiated · $84.66Nov 17Mar 23Jul 20Nov 15

Quote as of November 15, 2026, 12:23 PM ET

Company overview

Celcuity Inc. is a clinical-stage biotechnology company focused on targeted therapies for cancer, with its lead program centered on gedatolisib, a pan-PI3K/mTOR inhibitor. The company's business model is pre-commercial: it does not generate product revenue, and its operations are funded through equity issuance and, historically, partnerships. Value creation is therefore entirely dependent on clinical development success and eventual regulatory approval.

How it makes money (today): It does not. Revenue is effectively nil, and the company's income statement is dominated by research and development expense, which drives the -$4.30 EPS. The market cap of $3.9B reflects anticipated future cash flows from gedatolisib, not current operations.

Customers: In a pre-commercial biotech, the "customer" is ultimately the prescribing oncologist and the patient, but the near-term gatekeepers are regulators (FDA) and, if approved, payers. The commercial opportunity is defined by the HR+/HER2- metastatic breast cancer population that has progressed on CDK4/6 inhibitors.

Scale: With 48.93M shares outstanding, a 29.72M public float, and a $3.9B market cap, Celcuity is a mid-cap biotech by market value but a micro-cap by operational scale — it has no commercial infrastructure, no manufacturing footprint at scale, and a headcount consistent with a clinical-stage organization. The 0.20 beta and 1.15M average volume reflect a specialized, institutionally-driven shareholder base rather than broad retail ownership.

Growth outlook

Near-term (0–18 months): The dominant catalyst is clinical data from the gedatolisib program, particularly the VIKTORIA-1 trial in HR+/HER2- advanced breast cancer. Any readout — positive or negative — will likely move the stock far more than any financial metric, given the 34.83% short interest and thin float. Regulatory interactions (e.g., FDA meeting outcomes, potential Breakthrough Therapy or Fast Track designations) are secondary catalysts. Financing events are a third near-term driver: with negative EPS and no revenue, the company will need capital, and the terms of any raise will materially affect per-share value.

Medium-term (18–48 months): If the data support it, the path runs through a New Drug Application, potential approval, and commercial launch. Growth would then be a function of: (1) label breadth — whether gedatolisib is approved in the post-CDK4/6 setting only or more broadly; (2) competitive dynamics against approved PI3K inhibitors and emerging therapies; (3) pricing and reimbursement in a cost-conscious oncology environment; and (4) the company's ability to build or partner for commercial infrastructure. Expansion into earlier lines or additional tumor types could extend the runway, but each requires additional trials and capital.

Key swing factors: Clinical success, financing terms, competitive entries, and the durability of the post-CDK4/6 market opportunity as treatment paradigms evolve.

Financial analysis

Metric Historical (TTM) Projected (Year 1) Projected (Year 2) Projected (Year 3)
Revenue $0.0M $0.0M $0.0M–$50M* $150M–$400M*
Gross Margin N/A N/A N/A 80%–90%*
R&D Expense Elevated (drives -$4.30 EPS) Rising Rising Rising then plateauing
EPS -$4.30 Negative Negative to breakeven* Positive*

*Projections are illustrative scenarios contingent on clinical and regulatory success; they are not company guidance and should be treated as highly uncertain.

The financial story is simple: Celcuity currently has no revenue and a -$4.30 EPS, and the $3.9B market cap is a bet on future approval. The company's cash burn is driven by the gedatolisib program, and its ability to fund that burn depends on capital markets. A 29.72M public float and 34.83% short interest mean equity raises are likely to be dilutive and potentially volatile. The transition from negative to positive EPS is entirely contingent on a successful launch, and the timing of that transition is the single most important financial variable for long-term holders.

Industry & competitive landscape

Market size/TAM: HR+/HER2- breast cancer is the largest subtype of breast cancer, and the metastatic setting represents a multi-billion-dollar annual market globally. The post-CDK4/6 segment is a growing subset as first-line CDK4/6 use becomes universal. Even a modest share of this population would represent hundreds of millions in potential annual revenue.

Competitive positioning: Gedatolisib's pan-PI3K/mTOR mechanism differentiates it from isoform-selective inhibitors, but differentiation must be proven in trials. The competitive field is crowded and well-capitalized.

Named comparables:

  • Novartis (NVS): Markets alpelisib (Piqray), a PI3Kα-selective inhibitor approved in HR+/HER2- breast cancer with a PIK3CA mutation; also markets Kisqali (ribociclib), a leading CDK4/6 inhibitor.
  • Roche (RHHBY): Markets inavolisib (Itovebi), a PI3Kα-selective inhibitor approved in combination for PIK3CA-mutant HR+ breast cancer, and has broad oncology infrastructure.
  • AstraZeneca (AZN): Markets capivasertib (Truqap), an AKT inhibitor, in HR+/HER2- breast cancer, and also markets Faslodex and partners on CDK4/6 agents.
  • Pfizer (PFE): Markets palbociclib (Ibrance), the first CDK4/6 inhibitor, giving it deep commercial relationships in exactly the setting where gedatolisib would be used.

Celcuity's advantage is mechanistic breadth and a focused development strategy; its disadvantage is scale, capital, and the absence of commercial infrastructure relative to these large-cap competitors.

Valuation

DCF discussion: A discounted cash flow analysis for Celcuity is highly sensitive to two inputs: probability of clinical and regulatory success, and the timing of commercial launch. Using a risk-adjusted approach, the $3.9B market cap implies the market is assigning meaningful probability to gedatolisib approval and a multi-hundred-million-dollar peak sales opportunity. Because the company has no revenue and negative EPS of -$4.30, the DCF is effectively a probability-weighted option valuation rather than a conventional cash-flow model. Small changes in assumed probability of success (e.g., 40% vs. 60%) produce large swings in fair value, which explains the 52-week range of $44.42–$151.02.

Comparable-company multiples:

Company Ticker Market Cap Revenue (TTM) EV/Revenue Notes
Celcuity CELC $3.9B ~$0 N/A Clinical-stage; no product revenue
Novartis NVS Large-cap Multi-billion Low single-digit Diversified; alpelisib + Kisqali
Roche RHHBY Large-cap Multi-billion Low single-digit Diversified; inavolisib
AstraZeneca AZN Large-cap Multi-billion Mid single-digit Diversified; capivasertib
Pfizer PFE Large-cap Multi-billion Low single-digit Diversified; Ibrance

Traditional multiples are not meaningful for Celcuity given zero revenue; the stock trades on clinical optionality. Against large-cap comparables, CELC offers higher risk and higher potential reward, with no revenue cushion to absorb setbacks.

Investment thesis

Pillar 1: Pan-PI3K/mTOR Inhibition Is a Mechanistically Differentiated Approach

The PI3K/AKT/mTOR pathway is one of the most validated oncogenic drivers in HR+/HER2- breast cancer, but approved agents target individual nodes — alpelisib and inavolisib hit PI3Kα specifically, while everolimus hits mTOR. Gedatolisib inhibits all Class I PI3K isoforms and both mTORC1 and mTORC2, which the company argues may overcome the pathway reactivation that limits single-node inhibitors. If this mechanistic breadth translates into superior progression-free survival in the post-CDK4/6 setting, Celcuity could capture a meaningful share of a large, well-defined patient population. The financial impact is leveraged: a differentiated label in a multi-billion-dollar indication would justify a valuation far above the current $3.9B market cap, while a me-too profile would compress it toward cash value.

Pillar 2: The Post-CDK4/6 Metastatic Setting Is a Large, Underserved Market

CDK4/6 inhibitors are now standard first-line therapy in HR+/HER2- metastatic breast cancer, which means a growing population of patients eventually progresses and needs a second-line option. Endocrine resistance in this setting is poorly served, and the addressable population is expanding as first-line CDK4/6 use broadens. Celcuity's strategy of developing gedatolisib specifically in this post-CDK4/6 niche targets a clear unmet need rather than competing head-on in first-line, which reduces the commercial execution burden if approved.

Pillar 3: A Binary, Event-Driven Equity with Asymmetric Positioning

With 34.83% of float short and a 29.72M public float, CELC is structurally prone to violent moves around data. The 52-week range of $44.42–$151.02 and the 9.41% single-day move on 400,574 shares (roughly one-third of average volume) demonstrate how thin liquidity amplifies price action. For investors with high risk tolerance and a view on the VIKTORIA-1 readout, this creates the potential for outsized returns — but the same mechanics cut both ways, and the short interest means any negative data could trigger a cascade.

Pillar 4: Valuation Is Entirely Optionality, Not Earnings

With EPS of -$4.30 and no revenue, traditional metrics are inapplicable. The $3.9B market cap is effectively a probability-weighted option on gedatolisib approval and commercial success. This framing matters for position sizing: the stock should be underwritten as a venture-style binary, not a growth equity, and the 0.20 beta means it provides little portfolio diversification benefit despite its low index correlation.

Risks

  • Clinical/regulatory failure risk: Gedatolisib may fail to demonstrate sufficient efficacy or safety in pivotal trials, which would remove the majority of the equity value. This is the single largest risk and is binary in nature.
  • Financing and dilution risk: With -$4.30 EPS and no revenue, Celcuity depends on capital markets. A 29.72M public float and 34.83% short interest make equity raises dilutive and potentially destabilizing to the share price.
  • Competitive risk: Large-cap competitors (Novartis, Roche, AstraZeneca, Pfizer) have approved PI3K/AKT inhibitors and deep commercial infrastructure. Gedatolisib must show a clear advantage to gain share.
  • Liquidity and volatility risk: Average volume of 1.15M and a 29.72M float mean the stock can move violently on modest flows — the 9.41% single-day move on 400,574 shares is evidence. Short interest of 11.36M shares (34.83% of float) amplifies both directions.
  • Market/paradigm risk: If treatment paradigms shift (e.g., new mechanisms displace PI3K/mTOR inhibition in the post-CDK4/6 setting), the addressable opportunity could shrink even if gedatolisib is approved.

Build your Watchlist & Portfolio

Last price

$64.37

Log in to add CELC to your watchlist or simulate a trade.

Log in
Low$56.58High$84.66Initiate Price$84.66

Current $64.37

Coverage Metrics

Trend Direction

Down

Coverage High

$84.66

Coverage Low

$56.58

Initiate Price

$84.66

Current Price

$64.37

P&L

-23.97%

Quote as of November 15, 2026, 12:23 PM ET

Disclosure

This report was generated automatically by an AI-based research process, for educational and informational purposes only. It may not have been reviewed by a human for accuracy, completeness, or appropriateness prior to publication.

This report was not written or reviewed by a licensed securities analyst, investment adviser, or broker-dealer, and it does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security.

The rating, price target, and all financial estimates, projections, and comparisons in this report are model outputs generated from publicly available information, including market data, company filings, and news sources. They reflect known and unknown risks, uncertainties, and assumptions, and actual results may differ materially. Past performance is not indicative of future results.

Market and company data referenced in this report reflect the date the report was generated (or, for the "Current Price" figure shown separately from the report body, the most recent quote available when viewed) and may not reflect subsequent developments. StockWatch.report and its owners, employees, and contributors may hold long or short positions in any security discussed at any time.

Investing in securities involves risk, including the risk of loss of principal. You are solely responsible for your own investment decisions, and you should consult a licensed financial professional before making any investment decision based on this report. Use of this report and the Service is governed by, and subject to, our Terms and Conditions.

Key Data

Last

$84.66

Open

$81.30

Day Range

$79.78 - $88.68

P&L ($)

+$7.28

P&L (%)

+9.41%

Volume

400.57K

Previous Close

$77.38

Average Volume

1.15M

Rel. Volume

0.3×

Market Cap

$3.9B

Shares Outstanding

48.93M

Public Float

29.72M

Beta

0.20

EPS

$-4.30

Short Interest

11.36M (Sep 15, 2026)

% of Float Shorted

34.83%

As of September 30, 2026, 9:47 AM ET

Get the newsletter

Every trading day at 12:30 ET, free.

Advertise here
Stockwatch Reports

Free stock market updates, top gainers & losers, and AI-generated stock analyses — updated daily. Real-time price movements, quotes, and coverage for German & U.S. stoc